ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran
americanpharmaceuticalreview
August 22, 2018Alnylam has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias (AHPs).
Pharma Sources Insight January 2025
